Bepirovirsen Market Size, Share, Trends and Forecast 2026 To 2035
Bepirovirsen Market (By Baseline HBsAg Level: ≤100 IU/mL, >100 to ≤1,000 IU/mL, >1,000 to ≤3,000 IU/mL; By HBeAg Status: HBeAg-Negative, HBeAg-Positive; By End User: Hospital Hepatology & Gastroenterology Centers, Specialty Clinics, Community Health Centers & Others; By Distribution Channel: Specialty Pharmacies, Hospital Pharmacies, Retail & Online Pharmacies) - Global Industry Analysis, Size, Share, Regional Analysis, Trends and Forecast 2026 - 2035
- Last Updated: 23 Oct 2026
- Report Code: ARC4000
- Category: Healthcare and Pharmaceuticals
Bepirovirsen Market Size and Forecast 2026 to 2035
The global bepirovirsen market size is valued at USD 36.04 million in 2026 which is seen to reach at USD 266.13 million in 2027 and USD 2,116.99 million by 2035; growing at a promising CAGR of 29.6% during the forecast period of 2026-2035. The bepirovirsen market is expected to expand as functional-cure research advances for chronic hepatitis B. Regulatory approvals, clinical adoption, patient eligibility, reimbursement decisions, and access to specialist care will shape commercialization. Growing awareness of finite-course treatment options may further influence demand across healthcare systems.
The bepirovirsen market or hibsago market is taking a new turn after the drug received U.S. FDA approval on October 20, 2026. Company GSK has developed the drug in collaboration with Ionis Pharmaceuticals, which is one of the first FDA-approved anti-sense oligonucleotide drugs to treat hepatitis B. The drug can make a functional cure in adults in some cases of chronic hepatitis B following a short course of treatment.
Key Takeaways
- By region: North America is seen to dominate the bepirovirsen market in 2027, accounting for a 73.86% share and generating USD 196.56 million in revenue.
- By baseline HBsAg level: The >100 to ≤1,000 IU/mL segment is expected to dominate the baseline HBsAg category in 2027, with a 38.0% share.
- By HBeAg status: HBeAg-negative patients will dominate the HBeAg status segment in 2027, accounting for 84.0% of the market and generating $ 223.55 million.
- By end user: Hospital hepatology and gastroenterology centres will dominate the end-user segment in 2027, with a 58.0% share and $154.35 million.
- By distribution channel: Specialty pharmacies will dominate the distribution channel segment in 2027, accounting for a 48.0% share and generating $127.74 million in revenue.
Key Findings
- The FDA based its approval on two Phase III trials, B-Well 1 and B-Well 2, in which 19% of patients who received bepirovirsen achieved a functional cure compared to none who received placebo.
- The commercial opportunity arises from the presence of about 1.7 million patients with chronic hepatitis B in the United States where market players have traditionally won long-term hold on sale.
- Among participants with baseline HBsAg levels of 1,000 IU/mL or less, 200 of 768 patients, or 26%, achieved functional cure, compared with 0 of 393 patients in the placebo group. This highlights the importance of baseline viral-marker levels in assessing treatment outcomes.
Regulatory Landscape and Future Outlook
| Regulatory authority / market | Current regulatory status | Key regulatory requirements |
|---|---|---|
| United States (FDA) | Approved on October 20, 2026 | Approved for eligible adults without cirrhosis who meet the specified antiviral treatment, HBV DNA and HBsAg criteria. Companion diagnostic testing is authorized. |
| Japan (MHLW) | Approved on August 24, 2026 | Approval covers eligible adults with chronic hepatitis B who meet the specified prior-treatment and viral-marker criteria |
| European Union (EMA / European Commission) | Regulatory review was reported by GSK in March 2026; a final authorization should be verified against current official records. | Assessment of clinical efficacy, safety, manufacturing quality and the proposed product information. |
| China (NMPA) | Regulatory review was reported in March 2026; current approval status requires verification against official NMPA announcements. | Review of clinical evidence, product quality and local regulatory requirements. |
Bepirovirsen Market Dynamics
Growth Drivers
- Advancement in Chronic Hepatitis B Treatment: The need for more effective treatments for chronic hepatitis B is encouraging pharmaceutical developers to investigate therapies such as bepirovirsen, an antisense oligonucleotide designed to reduce hepatitis B viral proteins and potentially support functional cure strategies; which apparently acts as a major driver for hibsago market.
- Growing Focus on Novel Therapeutics: Advances in oligonucleotide chemistry, targeted RNA suppression, and clinical development are supporting research into antisense medicines, creating opportunities for bepirovirsen and other nucleic acid-based therapies targeting chronic viral infections.
Restraints
- Uncertainty Around Treatment Response: Bepirovirsen response may vary according to patient characteristics, baseline hepatitis B surface antigen levels, and other clinical factors, potentially limiting the proportion of patients who achieve a functional cure.
- High Clinical Development Costs: Developing a novel oligonucleotide therapy requires extensive clinical testing, specialized manufacturing, and regulatory review. These requirements can increase development expenses and create uncertainty around commercialization timelines and investment returns.
Opportunities
- Expansion of Eligible Patient Populations: FDA approval of Hibsago for specific adults with chronic hepatitis B creates opportunities to identify eligible patients through quantitative hepatitis B surface antigen testing and improve treatment access through specialist-led care pathways.
- International Regulatory Expansion: Regulatory approvals across additional markets could expand commercial access to bepirovirsen, particularly in regions with substantial chronic hepatitis B burdens and established diagnostic and antiviral treatment infrastructure.
- Development of Functional Cure Treatment Pathways: Bepirovirsen's potential to enable sustained viral control after treatment discontinuation creates opportunities for new care pathways combining patient selection, biomarker monitoring, and individualized treatment decisions.
Challenges
- Patient Eligibility and Treatment Selection: The approved indication covers a defined patient population, including adults without cirrhosis who meet specified antiviral treatment, viral suppression, and HBsAg criteria. Identifying eligible patients accurately will be important for market adoption.
- Safety Monitoring and Clinical Management: Potential serious liver reactions and thrombocytopenia require careful patient assessment and regular laboratory monitoring, creating additional clinical management requirements for healthcare providers and treatment centers.
Segmental Analysis
Baseline HBsAg Level Analysis
>100 to ≤1,000 IU/mL: The >100 to ≤1,000 IU/mL baseline HBsAg segment is projected to dominate the bepirovirsen market in 2027, accounting for 38.0% of the market, equivalent to $101.13 million. Its share is expected to increase to 39.0% by 2035, with revenue reaching $825.62 million. This category represents patients with intermediate baseline hepatitis B surface antigen levels within the report's defined range. Its projected leadership reflects the forecast allocation of market revenue to this patient subgroup.
Bepirovirsen Market Share, By Baseline HBsAg Level, 2027 & 2035 (%)
| Baseline HBsAg Level | Revenue Share, 2027 (%) | Revenue Share, 2035 (%) |
|---|---|---|
| <=100 IU/mL | 32% | 26% |
| >100 to <=1,000 IU/mL | 38% | 39% |
| >1,000 to <=3,000 IU/mL | 30% | 35% |
>1,000 to ≤3,000 IU/mL: The >1,000 to ≤3,000 IU/mL segment is projected to be the fastest-growing baseline HBsAg category, registering a CAGR of 32.1% from 2027 to 2035 in the hibsago market. Its market share is forecast to rise from 30.0% in 2027 to 35.0% in 2035, while revenue increases from $79.84 million to $740.94 million. The segment's forecast expansion indicates a growing contribution from patients in the higher HBsAg range included in the market model.
HBeAg Status Analysis
HBeAg-negative: HBeAg-negative patients are expected to be the majority of the hibsago market, with an estimated 84.0% of the market share by HBeAg status in 2027, an estimated 82.0% in 2035. The projection for a continued majority of HBeAg-negative patients to retain the larger share of the market is consistent with the market model's larger revenue share contribution for HBeAg-negative patients.
Bepirovirsen Market Share, By HBeAg Status, 2027 & 2035 (%)
| HBeAg Status | Revenue Share, 2027 (%) | Revenue Share, 2035 (%) |
|---|---|---|
| HBeAg-negative | 84% | 82% |
| HBeAg-positive | 16% | 18% |
HBeAg positive: The HBeAg-positive segment is expected to grow at a CAGR of 31.5% from 2027 to 2035, compared to 29.2% for the HBeAg-negative segment. Its market share is forecast to increase from 16.0% in 2027 to 18.0% in 2035; revenue is predicted to increase from $42.58 million to $381.06 million. The higher growth percentage has been calculated for a smaller base figure compared to the HBeAG-negative population segment.
End User Analysis
Hospital hepatology and gastroenterology centres: Hospital hepatology and gastroenterology centres are expected to hold the largest share within the hibsago market by end user in 2027, with 58.0% market share. Chronic hepatitis B assessment, specialist treatment selection, and watchful waiting are all important components of hospital hepatology and gastroenterology centres. The share of 58.0% in 2027, indicated by the forecast, is predicted to decrease over time to reflect a greater proportion of revenue in non-hospital care settings.
Community health centres & others: Care settings such as community health centres are expected to be the fastest growing end user segment through 2035 at a CAGR of 36.3% from 2027 to 2035. From 12.0% of the market in 2027, this is expected to increase to 18.0% by 2035. This more widespread access to treatment, and the potential for decentralized follow-up as care pathways are developed, may contribute to this segment's growth - although uptake will depend on local prescribing practices, ease of access to suitable clinical monitoring and the proliferation of care provision outside specialist hospitals.
Distribution Channel Analysis
Specialty pharmacies: Specialty pharmacies are projected to dominate the hibsago market by distribution channel in 2027, accounting for 48.0% of the market and $127.74 million in revenue. Their share is forecast to rise to 52.0% by 2035, with revenue reaching $1,100.83 million. Their projected position is consistent with the potential role of specialized dispensing, patient coordination, and support for complex prescription therapies. The extent of specialty pharmacy involvement will depend on payer requirements, manufacturer distribution arrangements, and country-specific dispensing regulations.
Retail and online pharmacies: Retail and online pharmacies are projected to record the fastest growth among the listed distribution channels, with a CAGR of 33.3% from 2027 to 2035. Despite this faster growth rate, the segment is forecast to remain smaller than specialty and hospital pharmacies throughout the period. Its actual role will depend on whether local regulations and prescribing practices permit these channels to dispense the treatment.
Bepirovirsen Market Regional Analysis
North America to Dominate the Bepirovirsen Market
North America is estimated to hold the highest share of the bepirovirsen market in 2027, at 73.86% of the global market, with revenues amounting to $196.56 million. The market in North America is foreseen to decline to 46.42% by 2035 with revenues amounting to $982.80 million, as other regions forecasted to grow faster. The market growth is foreseen due to the availability of treatment for chronic hepatitis B via a specialist-led chronic hepatitis B treatment, established diagnostic, and hepatology services along with the availability of novel therapies.
United States Bepirovirsen Market: Trends, Opportunities & Adoption Scope
- The U.S. Food and Drug Administration (FDA) approved Hibsago (bepirovirsen), developed by GSK, on October 20, 2026, for adults with chronic hepatitis B without cirrhosis who have received nucleos(t)ide analogue therapy for at least six months, have suppressed HBV DNA levels and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less.
- The commercial opportunity for hibsago will depend on its U.S. launch price, insurance coverage and patient affordability. Commercial insurers, Medicare and Medicaid may influence access through their respective coverage and reimbursement requirements.
- Hibsago's revenue potential will depend on the number of eligible patients identified, physician adoption, treatment completion, net pricing and insurance coverage.
Europe to Act as the Fastest-growing Marketplace
Europe is projected to be the fastest-growing regional market among the regions with reported CAGRs, expanding at 52.7% from 2027 to 2035. Its market share is forecast to increase from 6.76% in 2027 to 25.10% in 2035, while revenue rises from $17.99 million to $531.32 million. This projected growth reflects the potential impact of regulatory authorization, country-level market access, and the introduction of a new treatment option for eligible chronic hepatitis B patients.
Bepirovirsen Market Share, By Region, 2027 & 2035 (%)
| Region | Revenue Share, 2027 (%) | Revenue Share, 2035 (%) |
|---|---|---|
| North America | 73.86% | 46.42% |
| Europe | 6.76% | 25.10% |
| Japan | 16.09% | 8.61% |
| China | 3.29% | 9.94% |
| Rest of APAC | 0% | 6.51% |
| Latin America | 0% | 1.75% |
| MIddle East & Africa | 0% | 1.68% |
Japan Bepirovirsen Market: Trends, Opportunities & Adoption Scope
“Japan is projected to account for 16.09% of the Bepirovirsen Market in 2027, generating USD 42.83 million in revenue. Its share is expected to decline to 8.61% by 2035, with revenue reaching USD 182.20 million.”
- Japan approved bepirovirsen for adults with chronic hepatitis B who meet the specified clinical eligibility criteria. The treatment is intended for use alongside existing nucleos(t)ide analogue therapy, with patient selection based on hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA levels.
- Japan has an estimated one million people living with chronic hepatitis B, with the disease associated with approximately 4,000 deaths annually. Nationwide screening and treatment initiatives provide an established foundation for identifying patients who may benefit from new therapies.
- Japan's national health insurance system provides the framework for medicine reimbursement and patient access. The commercial opportunity for Hibsago will depend on its official reimbursement price, patient cost-sharing arrangements and coverage conditions.
China Bepirovirsen Marke: Trends, Opportunities & Adoption Scope
- "China is expected to hold 3.29% of the bepirovirsen market in 2027 with revenue of $8.75 million. China is estimated to hold 9.94% of the market by 2035 with a revenue of $210.36 million."
- China has a large chronic hepatitis B patient population, offering a potential uptake for new treatments that could lead to functional cure.
- The NMPA review of bepirovirsen was announced as accepted in March 2026. In May 2026, GSK revealed the companies had entered a strategic collaboration with Sino Biopharmaceutical to develop and commercialise bepirovirsen in China.
- The public health infrastructure in China and the existing clinical practice of antiviral therapy in chronic hepatitis B may support market adoption.
Competitive Landscape
- GSK plc: GSK is the commercial rights holder and developer of Hibsago (bepirovirsen), which received U.S. FDA approval in October 2026.
- Ionis Pharmaceuticals, Inc.: Ionis discovered bepirovirsen and partnered with GSK for its development and commercialization.
- Aligos Therapeutics: Aligos is developing pevifoscorvir sodium (ALG-000184), an oral capsid assembly modulator for chronic hepatitis B, alongside ALG-170675, an investigational antisense oligonucleotide.
- Arrowhead Pharmaceuticals, Inc. and Janssen: Arrowhead and Janssen have investigated JNJ-3989, also known as ARO-HBV, an RNA interference-based candidate designed to reduce hepatitis B viral proteins.
- Arbutus Biopharma Corporation: Arbutus has developed AB-729, an investigational RNA interference therapy designed to reduce hepatitis B surface antigen and other viral proteins.
Segments Covered
By Baseline HBsAg Level
- ≤100 IU/mL
- >100 to ≤1,000 IU/mL
- >1,000 to ≤3,000 IU/mL
By HBeAg Status
- HBeAg-Negative
- HBeAg-Positive
By End User
- Hospital Hepatology & Gastroenterology Centers
- Specialty Clinics (Office-Based Hepatology, Gastroenterology & Infectious Disease)
- Community Health Centers & Others
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
- Retail & Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa
Looking for discounts, bulk pricing, or custom solutions? Contact us today at sales@acumenresearchandconsulting.com
Frequently Asked Questions
The global bepirovirsen market size is valued at USD 36.04 million in 2026 and is expected to reach USD 2,116.99 million by 2035.
The global bepirovirsen market is growing at a promising CAGR of 29.6% during the forecast period of 2026-2035.
North America is seen to dominate the bepirovirsen market in 2027, accounting for a 73.86% share and generating USD 196.56 million in revenue.
The leading companies for bepirovirsen market are GSK plc, Ionis Pharmaceuticals, Inc., Aligos Therapeutics, Arrowhead Pharmaceuticals, Inc. and Janssen, Arbutus Biopharma Corporation and others.
Other Healthcare and Pharmaceuticals Reports
May 2024
December 2023
October 2024
June 2022